Cabaletta Bio, Inc. (CABA)

Market Cap	236.00M
Revenue (ttm)	n/a
Net Income (ttm)	-52.98M
Shares Out	31.34M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,292
Open	7.31
Previous Close	7.47
Day's Range	7.20 - 7.58
52-Week Range	0.59 - 12.88
Beta	2.57
Analysts	Buy
Price Target	13.77 (+82.87%)
Earnings Date	May 11, 2023

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune b...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA

Analyst Forecast

According to 13 analysts, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $13.77, which is an increase of 82.87% from the latest price.

Price Target

$13.77

(82.87% upside)

Analyst Consensus: Buy